Suppr超能文献

澳大利亚肝硬化住院治疗:澳大利亚原住民的临床表现和结局存在差异。

Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians.

机构信息

QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia.

Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.

出版信息

Int J Equity Health. 2020 Feb 17;19(1):27. doi: 10.1186/s12939-020-1144-6.

Abstract

BACKGROUND

Indigenous Australians experience greater health disadvantage and have a higher prevalence of many chronic health conditions. Liver diseases leading to cirrhosis are among the most common contributor to the mortality gap between Indigenous and other Australian adults. However, no comparative data exist assessing differences in presentation and patient outcomes between Indigenous and non-Indigenous Australians hospitalised with cirrhosis.

METHODS

Using data from the Hospital Admitted Patient Data Collection and the Death Registry, this retrospective, population-based, cohort study including all people hospitalised for cirrhosis in the state of Queensland during 2008-2017 examined rate of readmission (Poisson regression), cumulative survival (Kaplan-Meier), and assessed the differences in survival (Multivariable Cox regression) by Indigenous status. Predictor variables included demographic, health service characteristics and clinical data.

RESULTS

We studied 779 Indigenous and 10,642 non-Indigenous patients with cirrhosis. A higher proportion of Indigenous patients were younger than 50 years (346 [44%] vs. 2063 [19%] non-Indigenous patients), lived in most disadvantaged areas (395 [51%) vs. 2728 [26%]), had alcohol-related cirrhosis (547 [70%] vs. 5041 [47%]), had ascites (314 [40%] vs. 3555 [33%), and presented to hospital via the Emergency Department (510 [68%] vs. 4790 [47%]). Indigenous patients had 3.04 times the rate of non-cirrhosis readmissions (95%CI 2.98-3.10), 1.35 times the rate of cirrhosis-related readmissions (95%CI 1.29-1.41), and lower overall survival (17% vs. 27%; unadjusted hazard ratio (HR) = 1.16 95%CI 1.06-1.27), compared to non-Indigenous patients. Most of the survival deficit was explained by Emergency Department presentation (adj-HR = 1.03 95%CI 0.93-1.13), and alcohol-related aetiology (adj-HR = 1.08 95%CI 0.99-1.19). The remaining survival deficit was influenced by the other clinico-demographic and health service factors (final adj-HR = 1.08 95%CI 0.96-1.20).

CONCLUSIONS

There was evidence of differential presentation, higher rates of readmissions, and poorer survival for Indigenous Australians with cirrhosis, compared to other Australians. The increased prevalence of Emergency Department presentation among Indigenous patients suggests missed opportunities for early intervention to prevent progressive cirrhosis complications and hospital readmissions.

摘要

背景

澳大利亚原住民的健康状况较差,许多慢性健康状况的发病率更高。导致肝硬化的肝脏疾病是造成原住民和其他澳大利亚成年人之间死亡率差距的最常见原因之一。然而,目前尚无比较数据评估因肝硬化住院的原住民和非原住民澳大利亚人之间的表现和患者结局差异。

方法

本研究采用来自医院住院病人数据采集和死亡登记的数据,对 2008 年至 2017 年期间昆士兰州所有因肝硬化住院的患者进行回顾性、基于人群的队列研究,使用泊松回归评估再入院率,使用 Kaplan-Meier 评估累积生存率,并使用多变量 Cox 回归评估土著居民和非土著居民之间的生存差异。预测变量包括人口统计学、卫生服务特征和临床数据。

结果

我们研究了 779 名原住民和 10642 名非原住民肝硬化患者。更多的原住民患者年龄小于 50 岁(346 [44%] vs. 2063 [19%]非原住民患者),居住在最贫困地区(395 [51%] vs. 2728 [26%]),有酒精相关性肝硬化(547 [70%] vs. 5041 [47%]),有腹水(314 [40%] vs. 3555 [33%]),且通过急诊部入院(510 [68%] vs. 4790 [47%])。与非原住民患者相比,原住民患者的非肝硬化再入院率高 3.04 倍(95%CI 2.98-3.10),肝硬化相关再入院率高 1.35 倍(95%CI 1.29-1.41),总生存率低 17%(95%CI 106-1.27)。与非原住民患者相比,急诊部就诊(调整后的危险比(HR)=1.03,95%CI 0.93-1.13)和酒精相关性病因(调整后的 HR=1.08,95%CI 0.99-1.19)解释了大部分生存差异。其他临床人口统计学和卫生服务因素也影响了剩余的生存差异(最终调整后的 HR=1.08,95%CI 0.96-1.20)。

结论

与其他澳大利亚人相比,肝硬化的原住民澳大利亚人表现出不同的表现,再入院率更高,生存率更差。急诊部就诊的原住民患者比例增加表明,在肝硬化并发症和住院再入院进展之前,错过了早期干预的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1592/7027067/8479839ddeb0/12939_2020_1144_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验